Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, [IQWiG])
Record ID 32018001142
English
Authors' objectives:
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. This Joint Assessment aims to compare the clinical effectiveness and safety of polatuzumab vedotin in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.
Details
Project Status:
Completed
URL for project:
https://eunethta.eu/ptja06/
Year Published:
2020
URL for published report:
https://eunethta.eu/ptja06/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Antibodies, Monoclonal
- Bendamustine Hydrochloride
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Rituximab
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.